Mon, May 12, 9:34 PM (63 days ago)
**InMed Pharmaceuticals Inc. (INM) Q1 2025 Financial Summary** **Financial Health:** - **Cash Position:** $4.7 million in cash, cash equivalents, and short-term investments as of March 31, 2025. - **Operating Losses:** Net loss of $6.4 million for the nine months ended March 31, 2025. - **Accumulated Deficit:** $115.4 million as of March 31, 2025. - **Going Concern:** Substantial doubt about the ability to continue as a going concern within one year. **Performance Metrics:** - **Revenue:** $3.6 million for the nine months ended March 31, 2025. - **Gross Profit:** $1.1 million for the nine months ended March 31, 2025. - **Operating Expenses:** $7.3 million for the nine months ended March 31, 2025. - **Net Loss per Share:** $7.93 for the nine months ended March 31, 2025. **Cash Flow:** - **Operating Activities:** $6.0 million used in operating activities for the nine months ended March 31, 2025. - **Investing Activities:** No change in investing activities. - **Financing Activities:** $4.1 million provided by financing activities. **Earnings Changes:** - **Research and Development:** Increased by $256,000 for the nine months ended March 31, 2025. - **General and Administrative:** Increased by $249,000 for the nine months ended March 31, 2025. **Quarterly Performance Discussion:** - **Revenue Growth:** 10% increase in sales for BayMedica Commercial segment. - **Cost Management:** Decrease in cost of goods sold by 6% for BayMedica Commercial segment. - **Operating Expenses:** Increase in research and development expenses by 10% for InMed Pharma segment. **Trends and Uncertainties:** - **Market Demand:** Increased demand for certain cannabinoid products. - **Pricing Pressure:** Need to remain price competitive impacted overall profitability. - **Funding Requirements:** Dependence on additional capital to finance operations. **Future Operations Impact:** - **Clinical Trials:** Expectation of increased costs related to studies and drug supplies. - **Regulatory Requirements:** Higher costs associated with regulatory approvals. - **Strategic Transactions:** Potential for mergers, acquisitions, or licensing agreements. **Ticker:** INM